Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012
Top Cited Papers
- 1 September 2012
- journal article
- review article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (9) , 2846-2856
- https://doi.org/10.1128/jcm.00937-12
Abstract
Antifungal susceptibility testing of Candida has been standardized and refined and now may play a useful role in managing Candida infections. Important new developments include validation of 24-h reading times for all antifungal agents and the establishment of species-specific epidemiological cutoff values (ECVs) for the systemically active antifungal agents and both common and uncommon species of Candida . The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to provide species-specific interpretive criteria for the six most common species. The revised CBPs not only are predictive of clinical outcome but also provide a more sensitive means of identifying those strains with acquired or mutational resistance mechanisms. This brief review serves as an update on the new developments in the antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) methods.This publication has 100 references indexed in Scilit:
- FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based SurveillanceAntimicrobial Agents and Chemotherapy, 2010
- Mutational Analysis of Flucytosine Resistance in Candida glabrataAntimicrobial Agents and Chemotherapy, 2010
- Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest MediaAntimicrobial Agents and Chemotherapy, 2010
- A Ser29Leu Substitution in the Cytosine Deaminase Fca1p Is Responsible for Clade-Specific Flucytosine Resistance in Candida dubliniensisAntimicrobial Agents and Chemotherapy, 2009
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 2009
- Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniaeAntimicrobial Agents and Chemotherapy, 2009
- Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive BreakpointsAntimicrobial Agents and Chemotherapy, 2009
- Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard MethodAntimicrobial Agents and Chemotherapy, 2008
- Association of Fluconazole Pharmacodynamics with Mortality in Patients with CandidemiaAntimicrobial Agents and Chemotherapy, 2008
- A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin SusceptibilityAntimicrobial Agents and Chemotherapy, 2008